• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BETA Technologies and Multistate Collaborative Complete First Operational Flights of the U.S. DOT and FAA's eVTOL Integration Pilot Program

    7/10/26 12:35:00 PM ET
    $BETA
    $UTHR
    Aerospace
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BETA alert in real time by email

    The flights carried manufactured organs, being developed by United Therapeutics

    The flights are also the first in a series of use cases that will touch at least 26 states nationwide

    BETA Technologies, Inc. (BETA) (NYSE:BETA), an aerospace and defense company, and the Multistate Collaborative eIPP National Integration Complex today announced the completion of the first electric conventional takeoff and landing ("CTOL") aircraft flights conducted under the U.S. Department of Transportation ("U.S. DOT") and the Federal Aviation Administration ("FAA")’s eVTOL Integration Pilot Program ("eIPP"), the federal government's new initiative to evaluate how Advanced Air Mobility ("AAM") aircraft can safely operate in everyday commercial use within the National Airspace System ("NAS").

    The mission—conducted in partnership with the Pennsylvania Department of Transportation, the Virginia Department of Aviation, and the Maryland Aviation Administration—demonstrates BETA's ability to transform mission-critical logistics.

    The inaugural campaign demonstrated routine operations across a multistate corridor connecting Virginia and Maryland. The flights covered approximately 275 nautical miles, flying between Virginia Tech/Montgomery Executive Airport (KBCB) in Blacksburg, Virginia; Charlottesville-Albemarle Airport (KCHO) in Charlottesville, Virginia; Frederick Municipal Airport (KFDK) in Frederick, Maryland; and Martin State Airport (KMTN) in Baltimore County, Maryland. This milestone comes just months after BETA was selected to participate in seven of the FAA’s eight eIPP launch programs, more than any other electric aircraft developer.

    BETA and United Therapeutics Corporation (NASDAQ:UTHR), a biotech company at the forefront of increasing the supply of transplantable organs through their revolutionary organ manufacturing pipeline, have a long-standing partnership to develop and operate electric CTOL and vertical takeoff and landing ("VTOL") aircraft to deliver the manufactured organ products when they become commercially available. The partnership aims to reduce the cost, increase the reliability, and lower the carbon footprint of large-scale organ delivery operations. United Therapeutic’s subsidiary, Unither Bioelectronics, led by Mikael Cardinal, has advised and partnered with BETA on technologies including autonomy, aircraft aerostructures, and the strategic deployment of charging infrastructure.

    "United Therapeutics contracted BETA to build an electric aircraft capable of delivering lifesaving cargo, and today we delivered on that agreement," said Kyle Clark, founder and chief executive officer of BETA Technologies. "Our long-term partnership with United Therapeutics has shaped BETA and our mission to build the aircraft, infrastructure, and operational ecosystem. Since it began, we have safely flown our aircraft over 160,000 nautical miles and built charging infrastructure across 123 sites in the United States and Canada. Today’s successful missions, set the stage for routine medical applications through electric flight at a much lower cost nationwide."

    The eIPP was established by the U.S. DOT and the FAA to accelerate the safe integration of Advanced Air Mobility (AAM) through operational demonstrations that bring together aircraft manufacturers, operators, state and local governments, airports, and federal agencies. The program is intended to inform future certification policy, operational frameworks, and the broader commercialization of Advanced Air Mobility across the United States.

    "Our public-private partnerships are essential to safely unlocking the full potential of these revolutionary aircraft," said Chris Rocheleau, deputy FAA administrator. "Each eIPP project will showcase the broad public benefits of this technology—from moving people and cargo to supporting lifesaving emergency response—and the data we gather will help shape policies for safe, scalable operations nationwide."

    "Our mission to manufacture an unlimited supply of transplantable hearts, kidneys, lungs, and livers requires thousands of organ delivery flights per day," said Martine Rothblatt, CEO of United Therapeutics. "Our FDA-approved clinical trials for the heart, kidney, and bridge-liver, and this month’s FDA approval of our lung device, shows how quickly this mission is being achieved. Today's flight demonstrates how public-private collaboration can accelerate air transport innovation and thus help enable millions of lives to be saved over the coming decades."

    Anthony J. McCloskey, Bureau of Aviation Director at Pennsylvania Department of Transportation, said: "Today marks a significant step in the evolution of aviation! The use of next generation aviation technologies for critical future medical product delivery has successfully been demonstrated. PennDOT is thrilled to be leading the Multistate Collaborative eIPP National Integration Complex, which currently includes 17 other states, 4 OEMs, 3 Operators, and numerous other key stakeholders. Today's event truly exemplifies the strong partnership we've built and I am excited for the future of this technology!"

    "The Virginia Department of Aviation (DOAV) is honored to be a part of this monumental milestone showcasing the successful integration of AAM technologies into the Commonwealth of Virginia’s existing aviation infrastructure and the national air transportation system," said Greg Campbell, Director of DOAV. "Through continued collaboration with our partners, such as BETA Technologies and the FAA, along with our other state and federal counterparts, we remain committed to developing the AAM infrastructure needed to support these aircraft and deliver benefits nationwide.

    Shannetta R. Griffin, P.E. Executive Director/CEO Maryland Aviation Administration, said, "Maryland is incredibly proud to stand alongside our federal and regional partners in Virginia and Pennsylvania to celebrate this historic milestone. What BETA Technologies and United Therapeutics have achieved today is proof that zero-emission regional air mobility is no longer a concept for tomorrow—it can operate in our airspace today. By collaborating across state lines, we are proud to support a future where clean aviation can solve real-world, time-critical challenges like lifesaving organ transport."

    The Pennsylvania-Virginia-Maryland campaign marks the beginning of a broader national effort that will expand across additional states and mission profiles in the months ahead. The operational campaigns will help generate operational data and establish the framework for routine Advanced Air Mobility aircraft operations supporting healthcare, cargo, defense and other critical missions throughout the United States.

    For photos, please click here.

    About BETA Technologies, Inc.

    BETA (NYSE:BETA) is an aerospace and defense company designing, manufacturing and selling high-performance electric aircraft, advanced electric propulsion systems, components and charging systems to top operators worldwide. BETA has built and flown its family of ALIA aircraft, consisting of both conventional fixed-wing electric aircraft (the "ALIA CTOL") and electric vertical takeoff and landing aircraft (the "ALIA VTOL"), more than 160,000 nautical miles, including multiple trips across the United States. BETA is deploying a network of charging infrastructure to enable the growing industry with more than 100 sites across the United States and internationally. BETA’s intentional approach to developing the enabling technologies necessary to electrify aviation unlocks lucrative aftermarket revenue opportunity over the life of each aircraft. These highly scalable enabling technologies allow BETA to serve a customer base across cargo and logistics, defense, passenger and medical end markets and unlock cost-effective and safe missions. Visit www.beta.team for more information about BETA and its products.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260710568084/en/

    Media Contacts:

    BETA Technologies

    Press: Nat Bol, press@beta.team

    Investors: Devon Rothman, investors@beta.team

    Federal Aviation Administration

    Press: Hillary Heintz, pressoffice@faa.gov

    United Therapeutics

    Press: communications@unither.com

    Investors: https://ir.unither.com/contact-ir

    Pennsylvania Department of Transportation

    Press: Anthony McCloskey, amccloskey@pa.gov

    Virginia Department of Aviation

    Press: Greg Campbell, greg.campbell@doav.virginia.gov

    Maryland Aviation Administration

    Press: Sean Hammer, SHammer@bwiairport.com

    Get the next $BETA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BETA
    $UTHR

    CompanyDatePrice TargetRatingAnalyst
    United Therapeutics Corporation
    $UTHR
    5/7/2026$735.00Equal Weight → Overweight
    Wells Fargo
    United Therapeutics Corporation
    $UTHR
    4/10/2026$700.00Outperform
    Raymond James
    Beta Technologies Inc.
    $BETA
    2/11/2026$30.00Hold → Buy
    Jefferies
    Beta Technologies Inc.
    $BETA
    12/1/2025$34.00Overweight
    Morgan Stanley
    Beta Technologies Inc.
    $BETA
    12/1/2025$30.00Hold
    Jefferies
    Beta Technologies Inc.
    $BETA
    12/1/2025$47.00Buy
    Goldman
    Beta Technologies Inc.
    $BETA
    12/1/2025$41.00Buy
    Citigroup
    Beta Technologies Inc.
    $BETA
    12/1/2025$34.00Buy
    Needham
    More analyst ratings

    $BETA
    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE Aerospace Partners with NASA, BETA Technologies, and Boeing on World’s First High-Altitude Hybrid Electric Flight

    FARNBOROUGH, England, July 20, 2026 (GLOBE NEWSWIRE) -- Hybrid electric system enabled aircraft to reach more than 30,000 feetFirst public demonstration takes place at Farnborough International Airshow FARNBOROUGH, England – July 20, 2026 – GE Aerospace (NYSE:GE) announced today at the Farnborough International Airshow an industry first to advance the future of flight, demonstrating the viability of more electric aircraft engine systems for aviation. In collaboration with NASA, BETA Technologies, Inc. (NYSE:BETA) ("BETA") and Boeing, GE Aerospace conducted the first hybrid electric flight above 30,000 feet, reaching the same altitude levels of passenger commercial aircraft. Dur

    7/20/26 6:47:11 AM ET
    $GE
    $BETA
    Consumer Electronics/Appliances
    Technology
    Aerospace
    Industrials

    Loganair Adds BETA Technologies ALIA CTOL Aircraft to Its Fleet, Following Successful Demonstrations in United Kingdom

    Loganair signs term sheet with BETA Technologies for five ALIA CTOL (CX300) electric aircraft, with options for a further five Aircraft expected to enter service in 2029, positioning Loganair to become Europe's first commercial airline operating an electric aircraft fleet Loganair, the United Kingdom’s largest regional airline, and BETA Technologies (NYSE:BETA) ("BETA") today announced at the Farnborough International Airshow the signing of a term sheet under which Loganair will purchase five all-electric ALIA conventional takeoff and landing (CTOL) (CX300) aircraft, with options for five more. The UK, and Scotland in particular, is a natural first market for commercial electric fl

    7/20/26 6:45:00 AM ET
    $BETA
    Aerospace
    Industrials

    BETA Technologies Unveils MV250, Delivering Greater Range, Higher Speed, and Lower Costs for Military Logistics

    The MV250 delivers greater range and higher speed than similarly sized legacy platforms, and dramatically lowers procurement and operating costs compared to similarly sized legacy military platformsGE Aerospace and BETA jointly developed the turbogenerator enabling hybrid flight and ground-based power for expeditionary applicationsAutonomy is MOSA compliant with build-up flight tests successfully demonstrating both Sikorsky MATRIX and BETA autonomy systemsMV250 airframe and systems are common to BETA’s standard civil products lowering development, production and validation costsBETA Technologies (NYSE:BETA), an aerospace and defense company, today unveiled the MV250 at the Farnborough Intern

    7/20/26 5:00:00 AM ET
    $BETA
    $GE
    Aerospace
    Industrials
    Consumer Electronics/Appliances
    Technology

    $BETA
    $UTHR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $146.03 and sold $4,579,018 worth of shares (8,000 units at $572.38) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    5/27/26 4:30:25 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Stone Michael Robert bought $250,000 worth of shares (17,135 units at $14.59) (SEC Form 4)

    4 - BETA Technologies, Inc. (0001784570) (Issuer)

    5/21/26 5:40:09 PM ET
    $BETA
    Aerospace
    Industrials

    $BETA
    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Clark Kyle sold $87,592 worth of shares (5,000 units at $17.52) as part of a pre-agreed trading plan (SEC Form 4)

    4 - BETA Technologies, Inc. (0001784570) (Issuer)

    7/20/26 6:12:17 PM ET
    $BETA
    Aerospace
    Industrials

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $5,101,939 worth of shares (9,500 units at $537.05) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    7/20/26 4:32:21 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $5,043,689 worth of shares (9,500 units at $530.91) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    7/17/26 4:30:25 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BETA
    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    United Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded United Therapeutics from Equal Weight to Overweight and set a new price target of $735.00

    5/7/26 8:00:38 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on United Therapeutics with a new price target

    Raymond James initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $700.00

    4/10/26 8:35:42 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BETA Technologies upgraded by Jefferies with a new price target

    Jefferies upgraded BETA Technologies from Hold to Buy and set a new price target of $30.00

    2/11/26 7:41:32 AM ET
    $BETA
    Aerospace
    Industrials

    $BETA
    $UTHR
    SEC Filings

    View All

    SEC Form S-8 POS filed by United Therapeutics Corporation

    S-8 POS - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    7/13/26 6:41:43 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by United Therapeutics Corporation

    S-8 POS - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    7/13/26 6:40:53 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by United Therapeutics Corporation

    S-8 POS - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    7/13/26 6:39:26 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BETA
    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    11/8/24 4:30:29 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by United Therapeutics Corporation

    SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/16/24 1:03:48 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    6/10/24 12:15:17 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BETA
    $UTHR
    Financials

    Live finance-specific insights

    View All

    United Therapeutics Corporation Acquires Thymmune Therapeutics

    United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the immune system, including training T-cells, which are essential for fighting infections and other diseases. Thymmune has a proprietary process for converting human-induced pluripotent stem cells (iPSC) into thymic cells, which — once inside the body — mature into c

    7/2/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BETA Technologies, Inc. Announces First Quarter 2026 Results

    Leading the industry with seven eVTOL Integrated Pilot Program selections, BETA expanded strategic partnerships and accelerated its path to commercial operations BETA Technologies, Inc. (NYSE:BETA) ("BETA" or the "Company"), an electric aerospace company, today announced its financial and operating results for the first quarter ended March 31, 2026. "Since the beginning of the year, BETA has made critical progress in support of our stepwise approach to electrify aviation, demonstrating our leadership position in the advanced air mobility sector as we prepare to enter eIPP operations," said Kyle Clark, President and CEO. "We've created a complete system to bring electric aviation to mark

    5/12/26 4:30:00 AM ET
    $BETA
    Aerospace
    Industrials

    United Therapeutics Corporation Reports First Quarter 2026 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025. "In the first quarter of 2026, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "These readouts have the potential to meaningfully expand the breadth of our future growth and support further revenue diversification while

    5/6/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BETA
    $UTHR
    Leadership Updates

    Live Leadership Updates

    View All

    Archer Aviation, BETA Technologies and Macquarie Capital Launch ACES: America’s Consortium for Electric Skyways to Bring Interoperable Charging to 250+ Aviation Sites Across America by 2030

    Archer Aviation, BETA Technologies and Macquarie Capital are partnering to launch America’s Consortium for Electric Skyways (ACES), with a goal to electrify up to 250 air taxi sites across America's largest airports and metro areas over the next decade. The consortium will deploy BETA’s electric aviation chargers built on the Combined Charging Standard ("CCS") - the open charging standard endorsed by the General Aviation Manufacturers Association ("GAMA") and broadly adopted across the electric vertical takeoff and landing (eVTOL) industry. As selected participants in the FAA's eVTOL Integration Pilot Program ("eIPP"), the consortium will prioritize deploying charging infrastructure

    7/16/26 8:30:00 AM ET
    $ACHR
    $BETA
    Aerospace
    Industrials

    United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122174254/en/Kevin Tracey was recently elected to United Therapeutics' Board of Directors. Dr. Tracey is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Executive Vice Pres

    1/22/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

    1/27/21 8:00:00 AM ET
    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations